Toru Hosoda, MD, PhD
Tokai University Institute of Innovative Science and Technology, Isehara, Kanagawa, Japan.
After graduating and obtaining M.D. and Ph.D. degrees from the University of Tokyo, Dr. Hosoda carried out basic researches and clinical practices on cardiovascular medicine. Subsequently, over the last decade at the New York Medical College as well as at the Brigham and Women’s Hospital, Harvard Medical School, he has been committed to explore the field of regenerative medicine, especially the concept of myocardial renewal and repair by resident stem cells. After performing numerous investigations indicating the safety and efficacy of the stem cell administration in the preclinical settings of cardiac disease models, the group had moved on to the clinical arena; in the monumental SCIPIO trial, 20 severe ischemic heart failure patients received the injection of their own c-kit-positive cardiac stem cells following expansion in vitro, which demonstrated the feasibility and safety of this treatment. Now Dr. Hosoda has settled his own laboratory as an Associate Professor at the Tokai University in Japan and is founding a study group on translational regenerative medicine. The lab aims at the development of novel therapeutic strategies toward various cardiovascular diseases.